Status:
ACTIVE_NOT_RECRUITING
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
SARS-CoV Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to t...
Detailed Description
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to t...
Eligibility Criteria
Inclusion
- Any adult employee of the UZ Brussel at T1 who has been vaccinated at the UZ Brussel with mRNA COVID-19 vaccine (Comirnaty®) between the 19th of January and the 5th of February 2021 after participating to phase 4 of the COVEMUZ study (with a maximum of 5 days difference between blood drawel and vaccination) and has provided a signed informed consent.
Exclusion
- UZ Brussel employees not active during the inclusion period (T1).
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04880174
Start Date
March 22 2021
End Date
July 1 2028
Last Update
May 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitair ziekenhuis Brussel
Brussels, Belgium, 1090